Serum Anti-Ro52/Tripartite Motif-containing 21, A Novel Criterion of Interstitial Pneumonia With Autoimmune Features

Masahiro Tahara  
University of Occupational and Environmental Health Japan

Noriho Sakamoto  
Nagasaki University

Minoru Satoh  
University of Occupational and Environmental Health Japan

Hiroshi Ishimoto  
Nagasaki University

Hirokazu Yura  
Nagasaki University

Kei Yamasaki  
University of Occupational and Environmental Health Japan

Takashi Kido  
Nagasaki University

Yoshihisa Fujino  
University of Occupational and Environmental Health Japan

Tomoko Hasegawa  
University of Occupational and Environmental Health Japan

Shin Tanaka  
University of Occupational and Environmental Health Japan

Kazuhiro Yatera (✉ yatera@med.uoeh-u.ac.jp)  
University of Occupational and Environmental Health Japan

Hiroshi Mukae  
Nagasaki University

Research Article

Keywords: autoantibody, interstitial pneumonia with autoimmune features, idiopathic interstitial pneumonia, anti-Ro52/TRIM21 antibodies, systemic autoimmune rheumatic diseases

DOI: https://doi.org/10.21203/rs.3.rs-243049/v1
Abstract

**Background:** Antibodies to Ro52/tripartite motif-containing 21 (TRIM21), referred to as anti-Ro52, are found in patients diagnosed with diverse systemic autoimmune rheumatic disease and associated with interstitial lung diseases. However, little is known about the clinical characteristics of anti-Ro52 in patients with idiopathic interstitial pneumonias (IIPs). We aimed to analyze the prevalence, co-existent autoantibodies, and clinical characteristics of anti-Ro52 in patients with IIP.

**Methods:** The study enrolled 288 patients diagnosed with IIP. Serum anti-Ro52 was detected using enzyme-linked immunosorbent assay (ELISA). Co-existent autoantibodies, including anti-aminoacyl-tRNA synthetases (anti-ARS), were analyzed by immunoprecipitation. ELISA using recombinant antigens was performed as needed. Clinical, laboratory, and radiographic findings and survival of IIP patients were compared between anti-Ro52 positives and negatives.

**Results:** Anti-Ro52 (20/288; 6.9%), anti-ARS (18/288; 6.3%), and anti-Ro60/SS-A (16/288; 5.6%) were the most common autoantibodies detected in IIP patients. Among 20 IIP patients who had anti-Ro52, anti-ARS was present in 8 (40%), and anti-Ro60/SS-A was found in 6 (30%) patients. The criteria for interstitial pneumonia with autoimmune features (IPAF) were significantly better fulfilled by patients with anti-Ro52 than those without (P = 0.001). Meeting serological domain (P < 0.001) and Raynaud's phenomenon (P = 0.009) were significantly more common in the anti-Ro52-positive patients. There was no significant difference in the overall survival rate of IIP patients with vs. without anti-Ro52 (log-rank P = 0.51).

**Conclusion:** Anti-Ro52-positive IIP patients have clinical features consistent with IPAF. Adding anti-Ro52 in IPAF criteria may be considered in the future.

Background

Idiopathic interstitial pneumonias (IIPs) are diffuse fibrotic lung disorders that exclude known causes of interstitial lung diseases (ILDs) such as systemic autoimmune rheumatic disease (SARD), environmental exposure, and medication toxicity [1, 2]. Patients with IIP who have autoimmune features, but do not meet established diagnostic/classification criteria of SARD [3, 4] are categorized as “interstitial pneumonia with autoimmune features (IPAF)” [5]. Autoantibodies such as anti-aminoacyl-tRNA synthetases (anti-ARS) have proved clinically significant in diagnosis, treatment, and prediction of prognosis of IIP patients fulfilling the IPAF criteria [5-8].

Ro52/tripartite motif-containing 21 (TRIM21), an E3 ubiquitin ligase involved in ubiquitination, plays a prominent regulatory role in inflammation, apoptosis, and oxidative stress [9-11]. Anti-Ro52/TRIM21 antibodies (anti-Ro52) are commonly detected in the sera of patients diagnosed with different types of SARD, including Sjögren's syndrome [12], polymyositis/dermatomyositis (PM/DM) [13, 14], systemic sclerosis (SSc) [15, 16], and systemic lupus erythematosus (SLE) [17]. Co-existence of anti-Ro52 and anti-ARS (particularly anti-Jo-1 and anti-PL-7) is common in patients with PM/DM [14, 18, 19]. Anti-Ro52 is associated with the presence of ILD in SSc, PM/DM, and mixed connective tissue disease.
One study in PM/DM reported higher prevalence of ILD in patients with anti-Ro52 than without, however, it might be due to an association of anti-Ro52 and anti-ARS [14]. Another study on patients with anti-Ro52-positive ILD reported the absence of an established diagnosis of SARD in the majority (78%) of patients while nearly half (49.3%) fulfilled the IPAF criteria [21]. Further studies are warranted to explore the prevalence, co-existent autoantibodies, and clinical characteristics associated with the presence of anti-Ro52 in IIP patients.

This study aims to analyze the clinical significance of anti-Ro52 in patients with IIPs and the associated clinical and immunological characteristics. These findings may contribute to more accurate classification of IIP.

Methods

Study participants

A two-center retrospective cohort study was conducted by the Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, and the Department of Respiratory Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan. Patients with IIP were enrolled in the study between March 2007 and October 2016 (n = 288). At the first visit, IIP was diagnosed based on clinical, laboratory, and radiological findings as per the definition of the American Thoracic Society/European Respiratory Society (ATS/ERS) international multidisciplinary consensus classification [1, 2]. The study was conducted in accordance with the amended Declaration of Helsinki. The Institutional Review Board of the Nagasaki University Hospital, Nagasaki, Japan (Approval No: 16042517), and the University of Occupational and Environmental Health, (Approval No: H27-238) approved the protocol. Informed consent was obtained from all subjects. Observation and follow-up of each patient was conducted on an annual basis and was censored on April 30, 2020. Patients who were lost to follow-up were censored at the date of last contact/follow-up and those alive as on April 30, 2020, were censored for overall survival analyses.

Detection of serum autoantibodies

Serum samples of patients were obtained during their first visit and stored at −20 °C until further use. For the analyses of autoantibodies, 35S-methionine radiolabeled K562 cell extract was immunoprecipitated with IgG purified from 8 µL of human serum samples. The immunoprecipitated proteins were electrophoresed on sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) as described previously [22]. Briefly, cells were labeled with 35S-methionine and cysteine, lysed in 0.5 M NaCl, 2 mM ethylenediaminetetraacetic acid (EDTA), 50 mM Tris (pH 7.5), 0.3% octylphenyl polyethylene glycol (IGEPAL CA-630) buffer containing 0.5 mM phenylmethylsulfonyl fluoride and 0.3 trypsin inhibitory units (TIU)/mL aprotinin, and immunoprecipitated using protein-A-Sepharose beads coated with IgG. Immunoprecipitates were then washed with 0.5 M NaCl-NET/IGEPAL CA-630 and analyzed by SDS-PAGE and autoradiography. The specificity of autoantibodies was confirmed by the use of human reference
sera [22]. Antibodies to Ro52/TRIM21, histidyl-tRNA synthetase (Jo-1), and melanoma differentiation-associated protein 5 (MDA5) were tested by enzyme-linked immunosorbent assay (ELISA) as described previously [22]. All recombinant proteins were purchased from Diarect (Freiburg, Germany). Briefly, 96-well microtiter plates (Immobilizer Amino; Nunc Naperville, IL, USA) were coated with 0.5 μg/ml of recombinant protein and blocked with 0.5% bovine serum albumin (BSA)-NET/IGEPAL CA-630 for 1 h at room temperature. Patients’ sera (1:250) and alkaline phosphatase-conjugated goat anti-human IgG (1:1000; γ-chain specific; Jackson Immunoresearch, Hershey, PA, USA) diluted in 0.5% BSA-NET/IGEPAL CA-630 were used as the sample and secondary antibodies, respectively. A standard curve was generated using serial 1:5 dilutions of a high-titer prototype serum. Optical density of samples measured at 405 nm was converted into units based on the standard curve.

Anti-nuclear antibodies (ANA) and rheumatoid factor (RF) positivity was defined in accordance with the classification criteria of IPAF [5]: ANA titer ≥ 1:320, diffuse, speckled, homogeneous patterns; ANA any titer, nucleolar or centromere patterns; RF ≥ 2× upper limit of normal.

Clinical data collection and analyses

Demographic data, clinical information, results of laboratory and pulmonary function tests, and analyses of bronchoalveolar lavage fluid were obtained from medical records. Physical findings were confirmed by rheumatologists when appropriate. Classification criteria of IPAF were based on the 2015 ERS/ATS Task Force research statement [5]. During the observation period, none of the patients developed clinical or laboratory features associated with SARD diagnosis. Although patient data (n = 281) used in this study partially overlapped with a retrospective study published earlier [6], our research data related to anti-Ro52 are unique.

Radiographic Evaluation

At the first visit, patients were examined by high-resolution chest computed tomography (HRCT), and evaluated independently by two pulmonologists (N. S. and H. I.) for volume loss, distribution and presence of reticular shadows, honeycombing, traction bronchiectasis, ground-glass attenuation, consolidations, thickening of bronchovascular bundles, small nodules (φ < 5 mm), nodules (φ > 5 mm), and pleural effusion. According to the international IIPs classification [2], HRCT patterns were classified into usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), organizing pneumonia (OP), and diffuse alveolar damage (DAD).

Statistical analyses

Data are presented as the median [interquartile range] or frequency (%). Fisher’s exact test was used to compare categorical variables. Comparisons between groups were made using the Mann-Whitney U test. Survival analyses were performed using the Kaplan-Meier method and the log-rank test. All analyses were conducted at a significance level of α = 0.05. All statistical analyses were performed using the STATA 16.1 software (StataCorp, College Station, TX, USA).
Results

Autoantibodies in sera of patients with IIP

Of the 288 IIP patients enrolled in the study, ELISA revealed the presence of anti-Ro52 in the sera of 20 patients (6.9%) (Table 1). ANA and RF positivity in the serological domain of the IPAF were as follows; ANA titer ≥ 1:320, diffuse, speckled, homogeneous patterns (n = 20; 7.1%), ANA any titer, nucleolar or centromere patterns (n = 14; 5.0%), RF ≥ 2× upper limit of normal (n = 24; 9.4%). Anti-ARS was detected in 18 patients (6.3%), including autoantibodies to Jo-1 (n = 5; 1.7%), PL-7 (n = 2; 0.7%), PL-12 (n = 1; 0.3%), EJ (n = 4; 1.4%), OJ (n = 1; 0.3%), and KS (n = 5; 1.7%) (Table 1). In addition, autoantibodies to the following antigens were detected; Ro60/SS-A (n = 16; 5.6%), La/SS-B (n = 1; 0.3%), CCP (n = 9; 5.0%), double stranded DNA (n = 6; 3.3%), U1RNP (n = 2; 0.7%), topoisomerase I (Scl-70) (n = 1; 0.3%), MDA5 (n = 1; 0.3%), TIF1β (n = 2; 0.7%), CENP-A (n = 3; 1.0%), CENP-B (n = 2; 0.7%), and Anti-RNA Polymerase III (n = 1; 0.3%) (Table 1).

Autoantibodies co-existing with Anti-Ro52

Co-existence of anti-Ro52 with other autoantibodies was analyzed (Table 2). The presence of ANA (ANA titer ≥ 1:320, diffuse, speckled, or homogeneous patterns, 20% vs. 6.2%, P = 0.04), anti-ARS (40% vs. 3.7%, P < 0.001), and anti-Ro60/SS-A (30% vs. 3.7%, P < 0.001) was significantly more common in anti-Ro52-positive than in anti-Ro52-negative patients (Table 2). Among eight patients positive for both anti-ARS and anti-Ro52, three were positive for anti-Jo-1, two for anti-KS, and one each for anti-PL-7, anti-PL-12, and anti-EJ.

Anti-Ro52: patient characteristics and survival

Clinical characteristics of anti-Ro52-positive vs. -negative patients are summarized in Table 3. Anti-Ro52-positive patients frequently met the IPAF criteria (50% vs. 17%, P = 0.001), had the clinical domain of IPAF criteria (20% vs. 8%, P = 0.09), and showed a greater percentage of fulfillment of serological domain (75% vs. 26%, P < 0.001), but had similar prevalence of morphological domain (40% vs. 44%) compared to anti-Ro52-negative patients. Raynaud's phenomenon was significantly more common in anti-Ro52-positive than in anti-Ro52-negative patients (15% vs. 2%, P = 0.009). Laboratory findings indicated significantly higher levels of serum Krebs von den Lungen-6 (KL-6) in anti-Ro52-positive than in anti-Ro52-negative patients (1258 U/mL vs. 858 U/mL, P = 0.01) (Table 4). HRCT analyses revealed more frequent lower distribution (90% vs. 69%, P = 0.03) and less frequent ground-glass attenuations (45% vs. 72%, P = 0.02) in anti-Ro52-positive than in anti-Ro52-negative patients (Table 5). Significant differences were not detected in HRCT patterns in the presence or absence of serum anti-Ro52 in IIP patients. However, OP and DAD were seen exclusively in anti-Ro52-negative patients. Patient characteristics and details of each domain are shown in Supplementary Table S1 and S2. Kaplan-Meier curves showed no significant difference in the overall survival rate between patients with and without serum anti-Ro52 (log-rank P = 0.51) (Figure 1).
Anti-Ro52 in anti-ARS-positive cases: patient characteristics and survival

The clinical characteristics and survival of anti-Ro52-positive vs. -negative patients who were also positive for anti-ARS are summarized in Supplementary Tables S3–5 and Supplementary Figure S1. Clinical characteristics and Kaplan-Meier curves showed no significant difference in anti-ARS-positive patients with and without serum anti-Ro52.

Discussion

This is the first study investigating the frequency of serum anti-Ro52 antibodies in unselected patients with IIP. Similar to the prevalence of anti-ARS (6.3%), anti-Ro52 was detected in 6.9% of patients with IIP. Presence of serum anti-Ro52 was significantly associated with fulfillment of IPAF criteria, particularly with respect to the serological domain and Raynaud’s phenomenon, in IIP patients.

Anti-Ro52 is mostly present in patients with different types of SARD [23], as seen in nearly half of the patients with Sjögren's syndrome [12], SSc [15, 16], and SLE [17] and 20-30% of patients with PM/DM [13, 14]. In this study, the prevalence of anti-Ro52 (6.9%) in IIP was lower than in SARD but higher than in healthy individuals (<0.2%–1%) [24]. In addition, as in patients with PM/DM [14, 18, 19], anti-Ro52 frequently co-existed with anti-ARS. Among the anti-ARS that co-existed with anti-Ro52, anti-Jo-1 found in three cases was the most common, in addition to anti-PL-7, anti-PL-12, anti-EJ, and anti-KS.

IPAF criteria (P = 0.001) related to the serological domain (P < 0.001) were more frequently fulfilled by anti-Ro52-positive (50%) than anti-Ro52-negative patients (17%) in our IIP cohort. A previous retrospective study showed that 49.3% of the ILD patients who had anti-Ro52 met the IPAF criteria, similar to our result [21]. Anti-Ro52-positive patients could be negative in immunofluorescence ANA tests, however, anti-Ro52 was associated with IPAF serological domain, indicating that it frequently coexists with the other autoantibodies included in the IPAF serological domain (Table 2). Co-existence of anti-Ro52 with other specific autoantibodies in various SARD have been reported [14, 15, 18]. Although anti-Ro52 is not specific for a particular type of SARD diagnosis, a 14-fold increased risk of developing SARD was reported in IIP patients who met the IPAF criteria [25]. Thus, presence of anti-Ro52 might be considered as a useful clinical diagnostic tool for the early detection of IIP in patients who pose a higher risk of developing SARD in the future.

IPAF criteria are used for the identification of a subset of IIP patients exhibiting autoimmune features but lacking a definitive diagnosis of SARD [5]. The ATS/ERS task force has suggested the need for further validation and revision of IPAF criteria [5]. Accordingly, there has been a proposal for the inclusion of several myositis-specific antibodies (anti-NXP-2, anti-TIF1y) in the IPAF criteria [26]. In contrast, anti-double stranded DNA, anti-Sm, anti-topoisomerase I (Scl-70), and anti-MDA5 are disease-specific diagnostic antibodies that have a proven link to the diagnosis of SLE [27], SSc [28], and clinically amyopathic DM (CADM) [29]. These disease-specific marker antibodies are produced prior to the clinical manifestation of the associated CTD and the association of IPAF with these antibodies might be an indication of early stage CTD. The appropriateness of the inclusion of these antibodies in the IPAF criteria
is controversial. Nevertheless, we propose the addition of anti-Ro52 to the IPAF criteria because of its proven association with SARD and wide co-existence with other autoantibodies including anti-ARS in IIP patients, even prior to being diagnosed for SARD.

The frequency of Raynaud’s phenomenon was significantly higher in anti-Ro52-positive patients than in anti-Ro52-negative patients in our IIP cohort (P = 0.009) (Table 3). Nearly half of the IPAF patients exhibit at least one clinical domain with Raynaud’s phenomenon as the most common symptom [30, 31]. In this study, all three patients with anti-Ro52 who had Raynaud’s phenomenon were classified as IPAF (Supplementary Table S1 and S2). Thus, testing for serum anti-Ro52 might be helpful in classifying IIP patients with Raynaud’s phenomenon as those meeting the IPAF criteria. Raynaud’s phenomenon is associated with underlying or future development of SARD [32] but is not considered a predictor for its prognosis or development in IPAF patients [30, 31] probably due to the low prevalence and short follow-up periods. Thus, the clinical significance of Raynaud’s phenomenon in IPAF patients remains controversial.

Patients with anti-Ro52 have a higher frequency of rapidly progressive ILD and a higher rate of mortality than those without anti-Ro52 in SARD [13, 15, 16, 20]. Herein, presence of anti-Ro52 was not significantly associated with overall mortality, possibly due to the heterogeneity of IIPs and the limited number of patients.

Recent research has reported the heterogeneity related to the prognosis and response to treatment of IIP patients with anti-ARS, wherein, certain patients were refractory to treatment with poor prognosis, while others responded well [7, 33]. Patients with PM/DM positive for both anti-Ro52 and anti-ARS had severe myositis and joint impairment with a higher prevalence of ILD [14, 16]. In this study, among 18 anti-ARS-positive patients, significant differences were not seen in symptoms, characteristics (Supplementary Table S3–S5), and prognosis (Supplementary Figure S1) related to SARD, between anti-Ro52-positive and -negative patients. However, these findings might considerably be affected by the small number of IIP patients with anti-ARS and further research is thus required.

Several limitations of this study are acknowledged. First, this study was a retrospective study with variable follow-up intervals and periods. Second, the sample size was relatively small and comprised only of Japanese individuals from two university hospitals. Third, although none of the patients with IIP developed any autoimmune diseases during the follow-up period, the observation period was short. It is possible that some might develop SARD in the future because ILD could precede the development of SARD in certain patients [25].

Conclusions

The fulfillment of IPAF criteria and presence of Raynaud’s phenomenon were more frequently seen in the presence than in the absence of anti-Ro52 in patients with IIP. We propose the addition of anti-Ro52 to the IPAF criteria because of its association with different types of SARD and wide co-existence with other autoantibodies in the serological domain. Further prospective studies on a large cohort are needed to elucidate the clinical significance of anti-Ro52 in patients with IIP.
List Of Abbreviations

ANA, antinuclear antibodies; anti-ARS, anti-aminoacyl tRNA synthetases antibodies; anti-Ro52, anti-Ro52/TRIM21 antibodies; ATS/ERS, American Thoracic Society/European Respiratory Society; CADM, clinically amyopathic dermatomyositis; CTD, connective tissue disease; DAD, diffuse alveolar damage; ELISA, enzyme-linked immunosorbent assay; HRCT, high-resolution computed tomography; IIPs, idiopathic interstitial pneumonias; ILDs, interstitial lung diseases; IPAF, interstitial pneumonia with autoimmune features; KL-6, Krebs von den Lungen-6; MCTD, mixed connective tissue disease; NSIP, nonspecific interstitial pneumonia; OP, organizing pneumonia; PM/DM, polymyositis/dermatomyositis; RF, rheumatoid factor; SARD, systemic autoimmune rheumatic diseases; SLE, systemic lupus erythematosus; SSc, systemic sclerosis; TRIM21, tripartite motif-containing 21; UIP, usual interstitial pneumonia

Declarations

Ethics approval and consent to participate

The Institutional Review Board of the Nagasaki University Hospital, Nagasaki, Japan (Approval No: 16042517), and the University of Occupational and Environmental Health, (Approval No: H27-238) approved the protocol. Informed consent was obtained from all subjects.

Consent for publication

Not applicable

Availability of data and materials

The datasets used for the current study are available from the corresponding author on reasonable request.

Competing interests

The authors declare that they have no conflicts of interest (COI).

Funding

This work was supported by Japan society for the promotion of science (JSPS) KAKENHI (Grant-in-Aid for Scientific Research) [grant number 17K09617 to HM, 15K08790 and 19K08617 to MS].

Authors' contributions

MT designed the study, had full access to all the data in this study, performed statistical analyses, and wrote the initial draft. MS, TH, and ST tested autoantibodies in the sera by immunoprecipitation and ELISA. NS, MS, HI, KYatera, and HM made substantial contribution to the conception and design of the study. MT, NS, HI, HY, and TK acquired the data. NS, MS, KYamasaki, KYatera, and MH participated in
drafting and critically revising the article for important intellectual content. YF gave advice on the statistical analyses. KYatera was attributable for the final responsibility for the decision to submit the article for publication. All authors have read and approved the final manuscript.

Acknowledgements

Not applicable

Authors' information (optional)

Not applicable

References

1. American Thoracic Society, European Respiratory Society. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. This joint statement of the American Thoracic Society (ATS), and the European Respiratory Society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS Executive Committee, June 2001. Am J Respir Crit Care Med. 2002;165:277–304. https://doi.org/10.1164/ajrccm.165.2.ats01.

2. Travis WD, Costabel U, Hansell DM, King TE, Jr., Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–48. https://doi.org/10.1164/rccm.201308-1483ST.

3. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176:691–7. https://doi.org/10.1164/rccm.200702-220OC.

4. Vij R, Noth I, Strek ME. Autoimmune-featured interstitial lung disease: a distinct entity. Chest. 2011;140:1292–9. https://doi.org/10.1378/chest.10-2662.

5. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46:976–87. https://doi.org/10.1183/13993003.00150-2015.

6. Yura H, Sakamoto N, Satoh M, Ishimoto H, Hanaka T, Ito C, et al. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir Med. 2017;132:189–94. https://doi.org/10.1016/j.rmed.2017.10.020.

7. Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, et al.. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med. 2017;127:57–64. https://doi.org/10.1016/j.rmed.2017.04.007.
8. Tomonaga M, Sakamoto N, Ishimatsu Y, Kakugawa T, Harada T, Nakashima S, et al. Comparison of pulmonary involvement between patients expressing anti-PL-7 and anti-Jo-1 antibodies. Lung. 2015;193:79–83. https://doi.org/10.1007/s00408-014-9665-7.

9. Espinosa A, Hennig J, Ambrosi A, Anandapadmanaban M, Abelius MS, Sheng Y, et al. Anti-Ro52 autoantibodies from patients with Sjogren's syndrome inhibit the Ro52 E3 ligase activity by blocking the E3/E2 interface. J Biol Chem. 2011;286:36478–91. https://doi.org/10.1074/jbc.M111.241786.

10. Oke V, Wahren-Herlenius M. The immunobiology of Ro52 (TRIM21) in autoimmunity: a critical review. J Autoimmun. 2012;39:77–82. https://doi.org/10.1016/j.jaut.2012.01.014.

11. Arai T, Kagawa T, Sasaki Y, Sugawara R, Sugimoto C, Tachibana K, et al. Heterogeneity of incidence and outcome of acute exacerbation in idiopathic interstitial pneumonia. Respirology. 2016;21:1431–7. https://doi.org/10.1111/resp.12862.

12. Espinosa A, Zhou W, Ek M, Hedlund M, Brauner S, Popovic K, et al. The Sjogren's syndrome-associated autoantigen Ro52 is an E3 ligase that regulates proliferation and cell death. J Immunol. 2006;176:6277–85. https://doi.org/10.4049/jimmunol.176.10.6277

13. Cruellas MGP, dos Santos Trinidad Viana V, Levy-Neto M, de Souza FHC, Shinjo SK. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis. Clinics (Sao Paulo). 2013;68:909–14. https://doi.org/10.6061/clinics/2013(07)04.

14. Yamasaki Y, Satoh M, Mizushima M, Okazaki T, Nagafuchi H, Ooka S, Shibata T, Nakano H, Ogawa H, Azuma K, Maeda A, Tonooka K, Ito H, et al. Clinical subsets associated with different anti-aminoacyl transfer RNA synthetase antibodies and their association with coexisting anti-Ro52. Mod Rheumatol. 2016;26:403–9. https://doi.org/10.3109/14397595.2015.1091155.

15. Wodkowski M, Hudson M, Proudman S, Walker J, Stevens W, Nikpour M, et al. Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. Clin Exp Rheumatol 2015;33:S131–5.

16. Hudson M, Pope J, Mahler M, Tatibouet S, Steele R, Baron M, et al. Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. Arthritis Res Ther. 2012;14:R50. https://doi.org/10.1186/arg3763.

17. Smith S, Ni Gabhann J, McCarthy E, Coffey B, Mahony R, Byrne JC, et al. Estrogen receptor alpha regulates tripartite motif-containing protein 21 expression, contributing to dysregulated cytokine production in systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:163–72. https://doi.org/10.1002/art.38187.

18. Ghillani P, Andre C, Toly C, Rouquette AM, Bengoufa D, Nicaise P, et al. Clinical significance of anti-Ro52 (TRIM21) antibodies non-associated with anti-SSA 60kDa antibodies: results of a multicentric study. Autoimmun Rev. 2011;10:509–13. https://doi.org/10.1016/j.autrev.2011.03.004.

19. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13:367–71. https://doi.org/10.1016/j.autrev.2014.01.022.
20. Gunnarsson R, El-Hage F, Aalokken TM, Reiseter S, Lund MB, Garen T, et al. Associations between anti-Ro52 antibodies and lung fibrosis in mixed connective tissue disease. Rheumatology (Oxford) 2016;55:103–8. https://doi.org/10.1093/rheumatology/kev300.

21. Sclafani A, D'Silva KM, Little BP, Miloslavsky EM, Locascio JJ, Sharma A, et al. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. Respir Res 2019;20:256. https://doi.org/10.1186/s12931-019-1231-7.

22. Satoh M, Ceribelli A, Hirakata M, Chan EKL. Immunodiagnosis of autoimmune myopathies. In: Detrick B, Schmitz JL, Hamilton RG, editors. Manual of molecular and clinical laboratory immunology. Washington, DC; American Society of Microbiology Press; 2016. p. 878–87.

23. De Soyza A, McDonnell MJ, Goeminne PC, Aliberti S, Lonni S, Davison J, et al. Bronchiectasis rheumatoid overlap syndrome is an independent risk factor for mortality in patients with bronchiectasis: a multicenter cohort study. Chest. 2017;151:1247–54. https://doi.org/10.1016/j.chest.2016.12.024.

24. Satoh M, Chan EKL, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum. 2012;64:2319–27. https://doi.org/10.1002/art.34380.

25. Alevizos MK, Giles JT, Patel NM, Bernstein EJ. Risk of progression of interstitial pneumonia with autoimmune features to a systemic autoimmune rheumatic disease. Rheumatology (Oxford) 2020;59:1233–40. https://doi.org/10.1093/rheumatology/kez404.

26. De Sadeleer LJ, De Langhe E, Bodart N, Vigneron A, Bossuyt X, Wuyts WA. Prevalence of myositis-specific antibodies in idiopathic interstitial pneumonias. Lung 2018;196:329–33. https://doi.org/10.1007/s00408-018-0108-8.

27. Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677–86. https://doi.org/10.1002/art.34473.

28. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72:1747–55. https://doi.org/10.1136/annrheumdis-2013-204424.

29. Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014;16:465. https://doi.org/10.1007/s11926-014-0465-0.

30. Oldham JM, Adegunsoye A, Valenzi E, Lee C, Witt L, Chen L, et al. Characterisation of patients with interstitial pneumonia with autoimmune features. Eur Respir J. 2016;47:1767–75. https://doi.org/10.1183/13993003.01565-2015.

31. Sambataro G, Sambataro D, Torrisi SE, Vancheri A, Colaci M, Pavone M, et al. Clinical, serological and radiological features of a prospective cohort of interstitial pneumonia with autoimmune features (IPAF) patients. Respir Med. 2019;150:154–60. https://doi.org/10.1016/j.rmed.2019.03.011.
32. Belch J, Carlizza A, Carpentier PH, Constans J, Khan F, Wautrecht JC, et al. ESVM guidelines - the diagnosis and management of Raynaud's phenomenon. Vasa. 2017;46:413–23. https://doi.org/10.1024/0301-1526/a000661.

33. Watanabe K, Handa T, Tanizawa K, Hosono Y, Taguchi Y, Noma S, et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias. Respir Med. 2011;105:1238–47. https://doi.org/10.1016/j.rmed.2011.03.022.

Tables

Table 1. Prevalence of autoantibodies in idiopathic interstitial pneumonitis (IIP) patients
| Autoantibodies                                                                 | Prevalence n (%) | Numbers tested n |
|-------------------------------------------------------------------------------|------------------|------------------|
| Anti-Ro52                                                                     | 20 (6.9)         | 288              |
| ANA titer ≥ 1:320, diffuse, speckled, or homogeneous patterns                 | 20 (7.1)         | 280              |
| ANA any titer, nucleolar or centromere patterns                               | 14 (5.0)         | 280              |
| Rheumatoid factor ≥ 2× upper limit of normal                                  | 24 (9.4)         | 255              |
| Anti-ARS                                                                      | 18 (6.3)         | 288              |
| Anti-Jo-1                                                                     | 5 (1.7)          | 288              |
| Anti-PL-7                                                                     | 2 (0.7)          | 288              |
| Anti-PL-12                                                                    | 1 (0.3)          | 288              |
| Anti-EJ                                                                       | 4 (1.4)          | 288              |
| Anti-OJ                                                                       | 1 (0.3)          | 288              |
| Anti-KS                                                                       | 5 (1.7)          | 288              |
| Anti-Ro60/SS-A                                                                | 16 (5.6)         | 288              |
| Anti-La/SS-B                                                                  | 1 (0.3)          | 288              |
| Anti-CCP                                                                      | 9 (5.0)          | 180              |
| Anti-double stranded DNA                                                      | 6 (3.3)          | 183              |
| Anti-U1RNP                                                                    | 2 (0.7)          | 288              |
| Anti-Sm                                                                       | 0 (0)            | 288              |
| Anti-topoisomerase I (Scl-70)                                                 | 1 (0.3)          | 288              |
| Anti-PM-Scl                                                                   | 0 (0)            | 288              |
| Anti-MDA5                                                                     | 1 (0.3)          | 288              |
| Anti-TIF1β                                                                    | 2 (0.7)          | 288              |
| Anti-CENP-A                                                                   | 3 (1.0)          | 288              |
| Anti-CENP-B                                                                   | 2 (0.7)          | 288              |
| Anti-RNA Polymerase III                                                       | 1 (0.3)          | 288              |

Data presented as frequencies (%)

Ro52: Ro52/tripartite motif-containing 21; ANA: anti-nuclear antibody; ARS: aminoacyl-tRNA synthetases; CCP: cyclic citrullinated peptide; MDA5: melanoma differentiation-associated gene 5; TIF1: transcriptional intermediary factor 1; CENP: centromere protein
Table 2. Antibodies co-existing with anti-Ro52/tripartite motif-containing 21 antibodies (anti-Ro52)
|                                | Anti-Ro52 positive | Anti-Ro52 negative | $P$ value |
|--------------------------------|--------------------|--------------------|-----------|
| **Subjects**                   | n = 20             | n = 268            | –         |
| n (%)                          |                    |                    |           |
| **ANA titer $\geq 1:320$, diffuse, speckled, or homogeneous patterns** | 4 (20)             | 16 (6.2)           | 0.04      |
| **ANA any titer, nucleolar or centromere patterns** | 3 (15)             | 11 (4.2)           | 0.07      |
| **Rheumatoid factor $\geq 2\times$ upper limit of normal** | 3 (20)             | 21 (8.8)           | 0.16      |
| **Anti-ARS**                   | 8 (40)             | 10 (3.7)           | $<0.001$  |
| Anti-Jo-1                      | 3 (15)             | 2 (0.7)            | 0.003     |
| Anti-PL-7                      | 1 (5)              | 1 (0.4)            | 0.13      |
| Anti-PL-12                     | 1 (5)              | 0 (0)              | 0.07      |
| Anti-EJ                        | 1 (5)              | 3 (1.1)            | 0.25      |
| Anti-OJ                        | 0 (0)              | 1 (0.4)            | 0.93      |
| Anti-KS                        | 2 (10)             | 3 (1.1)            | 0.04      |
| **Anti-Ro60/SS-A**             | 6 (30)             | 10 (3.7)           | $<0.001$  |
| **Anti-La/SS-B**               | 0 (0)              | 1 (0.4)            | 0.93      |
| **Anti-CCP**                   | 0 (0)              | 9 (5.4)            | 0.47      |
| **Anti-double stranded DNA**   | 0 (0)              | 6 (3.6)            | 0.57      |
| **Anti-U1RNP**                 | 1 (5)              | 1 (0.4)            | 0.13      |
| **Anti-Sm**                    | 0 (0)              | 0 (0)              | –         |
| **Anti-topoisomerase I (Scl-70)** | 0 (0)              | 1 (0.4)            | 0.93      |
| **Anti-PM-Scl**                | 0 (0)              | 0 (0)              | –         |
| **Anti-MDA5**                  | 0 (0)              | 1 (0.4)            | 0.93      |
| **Anti-TIF1β**                 | 0 (0)              | 2 (0.7)            | 0.87      |
| **Anti-CENP-A**                | 0 (0)              | 3 (1.1)            | 0.81      |
| **Anti-CENP-B**                | 0 (0)              | 3 (1.1)            | 0.87      |
| **Anti-RNA Polymerase III**    | 0 (0)              | 1 (0.4)            | 0.93      |

Data presented as frequencies (%)

Ro52: Ro52/tripartite motif-containing 21; ANA: anti-nuclear antibody; ARS: aminoacyl-tRNA synthetases; CCP: cyclic citrullinated peptide; MDA5: melanoma differentiation-associated
Table 3. Clinical characteristics of patients in the presence or absence of anti-Ro52/tripartite motif-containing 21 antibodies (anti-Ro52)
|                               | All     | Anti-Ro52 positive | Anti-Ro52 negative | P value |
|-------------------------------|---------|--------------------|--------------------|---------|
| Subjects                      | n = 288 | n = 20             | n = 268            | –       |
| Age (years)                   | 69.5 [63–75] | 67.5 [63–74]       | 70 [63–75]         | 0.35    |
| Male, n (%)                   | 193 (67) | 11 (55)            | 182 (68)           | 0.17    |
| Smoking (Pack-years)          | 22 [0–48] | 19 [0–42]          | 23 [0–49]          | 0.79    |
| Fulfilled IPAF criteria, n (%)| 55 (19)  | 10 (50)            | 45 (17)            | 0.001   |
| Clinical Domain, n (%)        | 26 (9)  | 4 (20)             | 22 (8)             | 0.09    |
| Serological Domain, n (%)     | 86 (30) | 15 (75)            | 71 (26)            | <0.001  |
| Morphological Domain, n (%)   | 127 (44)| 8 (40)             | 119 (44)           | 0.44    |
| Respiratory Symptoms          |         |                    |                    |         |
| Cough#, n (%)                 | 164 (59)| 12 (63)            | 152 (59)           | 0.47    |
| Sputum¶, n (%)                | 62 (23) | 2 (11)             | 60 (24)            | 0.15    |
| Dyspnea⁺, n (%)               | 177 (67)| 15 (83)            | 162 (66)           | 0.10    |
| Clinical symptoms related to SARD |     |                    |                    |         |
| Mechanic's hands§, n (%)      | 3 (1)   | 1 (5)              | 2 (1)              | 0.20    |
| Distal digital tip ulceration†, n (%) | 2 (1) | 0 (0)       | 2 (1)              | 0.87    |
| Inflammatory arthritis‡, n (%)| 15 (5)  | 1 (5)              | 14 (5)             | 0.72    |
| Palmar telangiectasia§, n (%) | 0 (0)   | 0 (0)              | 0 (0)              | –       |
| Raynaud's phenomenon§, n (%)  | 7 (2)   | 3 (15)             | 4 (2)              | 0.009   |
| Unexplained digital edema§, n (%) | 2 (1) | 0 (0)       | 2 (1)              | 0.864   |
| Gottron's sign‡, n (%)        | 0 (0)   | 0 (0)              | 0 (0)              | –       |
| Muscle weakness##, n (%)       | 2 (1)   | 0 (0)              | 2 (1)              | 0.87    |
| Weight loss¶¶, n (%)          | 15 (5)  | 1 (5)              | 14 (5)             | 0.71    |
| Dry mouth or dry eye‡, n (%)  | 7 (2)   | 0 (0)              | 7 (3)              | 0.60    |
| Dysphagia‡, n (%)             | 6 (2)   | 0 (0)              | 6 (2)              | 0.65    |
| Gastroesophageal reflux       | 23 (36) | 1 (25)             | 22 (37)            | 0.55    |
Table 4. Tests and findings of patients with/without anti-Ro52/tripartite motif-containing 21 antibodies (anti-Ro52)
|                              | All | Anti-Ro52 positive | Anti-Ro52 negative | P value |
|------------------------------|-----|--------------------|--------------------|---------|
| **Subjects**                 |     |                    |                    |         |
| n                            | 288 | 20                 | 268                | -       |
| **Laboratory findings**      |     |                    |                    |         |
| CRP (mg/dL)<sup>#</sup>     | 0.48 [0.12–2.66] | 0.30 [0.17–1.73]  | 0.49 [0.12–2.7]  | 0.93    |
| LDH (IU/L)<sup>¶</sup>       | 225 [192–288]    | 226 [187–291]     | 225 [193–288]     | 0.54    |
| CK (IU/L)<sup>+</sup>        | 74 [51–114]      | 77 [55–126]       | 73 [51–113]       | 0.42    |
| KL-6 (U/mL)<sup>§</sup>      | 878 [491–1554]   | 1258 [807–2604]   | 858 [476–1462]    | 0.01    |
| SP-A (ng/mL)<sup>ƒ</sup>     | 73 [49–107]      | 87 [72–109]       | 72 [47–107]       | 0.36    |
| SP-D (ng/mL)<sup>##</sup>    | 220 [118–340]    | 180 [121–335]     | 220 [118–341]     | 0.91    |
| **Pulmonary function tests<sup>¶¶</sup>** |     |                    |                    |         |
| VC (% predicted)             | 79 [64–94]       | 76 [63–85]        | 80 [64–95]        | 0.36    |
| FEV<sub>1</sub>/FEV (% predicted) | 82 [76–88]     | 81 [78–86]        | 82 [76–88]        | 0.78    |
| DL<sub>CO</sub> (% predicted) | 59 [42–74]     | 63 [41–68]        | 58 [42–74]        | 0.76    |
| **Bronchoalveolar lavage fluid<sup>++</sup>** |     |                    |                    |         |
| TCC (×10<sup>5</sup>/mL)    | 2.8 [1.8–4.5]    | 2.9 [1.7–4.9]     | 2.8 [1.8–4.5]     | 0.84    |
| Macrophages (%)             | 69.1 [50.3–80.6] | 76.9 [62.0–78.9]  | 68.7 [50.0–80.7]  | 0.43    |
| Lymphocytes (%)             | 12.7 [6.5–28.1]  | 10.8 [6.2–18.2]   | 12.8 [6.5–18.1]   | 0.39    |
| Neutrophils (%)             | 6.3 [2.9–13.5]   | 4.5 [2.8–10.3]    | 6.6 [2.9–13.6]    | 0.64    |
| Eosinophils (%)             | 3.1 [1.1–6.2]    | 3.3 [1.3–4.3]     | 3.1 [1.1–6.3]     | 0.80    |
| CD4/CD8                     | 1.7 [0.8–2.7]    | 1.4 [0.4–3.5]     | 1.7 [0.8–2.7]     | 0.60    |

Data presented as median [interquartile range] or frequencies (%)

n = 288, unless otherwise stated; <sup>#</sup>: n = 279; <sup>¶</sup>: n = 278; <sup>+</sup>: n = 229; <sup>§</sup>: n = 260; <sup>ƒ</sup>: n = 137; <sup>##</sup>: n = 210; <sup>¶¶</sup>: n = 209; <sup>++</sup>: n = 218

Ro52: Ro52/tripartite motif-containing 21; CRP: C-reactive protein; LDH: lactate
dehydrogenase; CK: creatine kinase; KL-6: Krebs von den Lungen-6; SP-A: surfactant protein-A; SP-D: surfactant protein-D; VC: vital capacity; FEV$_1$: forced expiratory volume in one second; DL$_{CO}$: diffusing capacity of the lung for carbon monoxide; TCC: total cell counts; CD: cluster of differentiation

Table 5. Results and patterns of patients with/without anti-Ro52/tripartite motif-containing 21 antibodies (anti-Ro52)
| HRCT findings                  | All      | Anti-Ro52 positive | Anti-Ro52 negative | P value |
|-------------------------------|----------|--------------------|--------------------|---------|
|                               | n = 288  | n = 20             | n = 268            | –       |
|                               | n (%)    | n (%)              | n (%)              |         |
| HRCT findings                 |          |                    |                    |         |
| Volume loss                   | 201 (70) | 17 (85)            | 184 (69)           | 0.10    |
| Lower distribution            | 201 (70) | 18 (90)            | 183 (69)           | 0.03    |
| Subpleural distribution       | 200 (69) | 13 (65)            | 187 (70)           | 0.41    |
| Peribronchial distribution    | 40 (14)  | 3 (15)             | 37 (14)            | 0.55    |
| Reticular shadow              | 241 (84) | 18 (90)            | 223 (84)           | 0.34    |
| Honeycombing                  | 110 (38) | 10 (50)            | 100 (38)           | 0.19    |
| Traction bronchiectasis       | 228 (79) | 19 (95)            | 209 (79)           | 0.052   |
| Ground-glass attenuation      | 200 (69) | 9 (45)             | 191 (72)           | 0.02    |
| Consolidation                 | 88 (31)  | 4 (20)             | 84 (32)            | 0.21    |
| Thickening of BVB             | 7 (2)    | 1 (5)              | 6 (2)              | 0.40    |
| Small nodules (φ < 5 mm)      | 17 (6)   | 0 (0)              | 17 (6)             | 0.28    |
| Nodules (φ > 5 mm)            | 13 (5)   | 1 (5)              | 12 (5)             | 0.62    |
| Pleural effusion              | 14 (5)   | 0 (0)              | 14 (5)             | 0.36    |
| HRCT pattern                  |          |                    |                    |         |
| UIP                           | 120 (42) | 9 (45)             | 111 (42)           | 0.46    |
| NSIP                          | 91 (32)  | 9 (45)             | 82 (31)            | 0.14    |
| OP                            | 31 (11)  | 0 (0)              | 31 (12)            | 0.09    |
| DAD                           | 11 (4)   | 0 (0)              | 11 (4)             | 0.45    |
| Others                        | 35 (12)  | 2 (10)             | 33 (12)            | 0.55    |

Data presented as frequencies (%)
P value: anti-Ro52 positive vs. anti-Ro52 negative